Navigation Links
Mylan Reports a 13% Increase in Second Quarter 2013 Adjusted Diluted EPS to $0.68
Date:8/1/2013

increase in revenues in France as a result of new product revenue and favorable volume. Partially offsetting this increase was unfavorable pricing in a number of European markets in which Mylan operates as a result of government imposed pricing reductions and competitive market conditions.

Third party net revenues from Asia Pacific were $357.4 million for the current quarter, compared to $307.5 million for the comparable prior year period, an increase of $49.9 million, or 16.2%. However, foreign currency translation had an unfavorable impact on sales for the current quarter, principally reflecting the significant strengthening of the U.S. Dollar versus the Indian Rupee and Japanese Yen. Excluding the effect of foreign currency translation, calculated as described above, third party net revenues would have increased by approximately $75 million, or 24%. This increase is primarily driven by higher revenues by Mylan India, as a result of increased sales of antiretroviral finished dosage form generic products, which are used in the treatment of HIV/AIDS, and an increase in sales of active pharmaceutical ingredients (API). In addition, local currency revenues increased in Japan due to higher volumes and new product introductions.

For the current quarter, Mylan's Specialty segment reported third party net sales of $236.9 million, an increase of $30.3 million, or 14.7%, from the comparable prior year period of $206.6 million. The most significant contributor to Specialty segment revenues continues to be the EPIPEN® Auto-Injector, sales of which increased as a result of favorable pricing and volume. The EPIPEN® Auto-Injector is the number one epinephrine auto-injector for the treatment of severe allergic reactions.

Gross profit for the three months ended June 30, 2013, was $742.4 million and gross margins were 43.6%. For the three months ended June 30, 2012, gross profit was $702.6 million, and gross margins were 41.6%. Adjusted gross prof
'/>"/>

SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Related medicine technology :

1. Third Circuit Rules in Mylans Favor Regarding Paroxetine Hydrochloride Extended-Release Tablets, Sending Mylans Breach of Contract Claim Against GSK to Trial
2. Mylan to Host Investor Day on Aug. 1, 2013 in New York City
3. Roger Graham Named President of Mylan Specialty
4. Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign
5. Mylan to Speak at the Goldman Sachs 34th Annual Global Healthcare Conference
6. New Breakthroughs Allow Companies to Expand their Reach - Research Report on Perrigo, Auxilium, Actavis, Mylan, and Salix
7. Mylan Specialty L.P. Announces Partnership with Baseball Teams Across Country to Raise Awareness of Potentially Life-Threatening Allergies
8. Presenting Sponsor Mylan Specialty L.P. Calls on Communities Nationwide to Join The Food Allergy Research & Education (FARE) Walk for Food Allergy
9. Mylan Reports a 19% Increase in First Quarter 2013 Adjusted Diluted EPS to $0.62
10. Deborah Autor, FDAs Deputy Commissioner for Global Regulatory Operations and Policy, to Join Mylan
11. Mylan Announces $1 Million Gift to The Pittsburgh Promise Scholarship Fund
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015 VWR (NASDAQ: ... and solutions, announces the redesign of its global website, ... When visiting the new site, guests will enjoy enhanced ... and vivid images.  Each country site now includes: ... Z product menu; and , the ability to search ...
(Date:8/3/2015)... -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) today announced ... Investor Conference Call and webcast at 4:30 p.m., Eastern time, ... cover an update on Merrimack,s progress as well as ... release detailing the information to be discussed on the ... 10. Investors and the general public are invited to ...
(Date:8/3/2015)... and FLORHAM PARK, N.J. , Aug. ... naldemedine met its primary and secondary endpoints in a ... opioid-induced constipation (OIC) in adult patients with chronic non-cancer ... receptor antagonist (PAMORA). This is the third Phase III ... secondary endpoints. Study results showed that a ...
Breaking Medicine Technology:VWR's New Website Redesign Provides Improved Functionality for Customers 2Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
... , PARSIPPANY, N.J. , Jan. 14 ... the spine market, the company has announced the addition of ... individuals filling these positions bring a deep knowledge of the ... developing strong distribution networks in their respective areas.   , ...
... , , ... Jan. 14 ImproMed, Inc. creators of the Infinity ... home delivery services on behalf of veterinarians, announce the integration ... immediately with the release of v4.5 of Infinity, veterinarians can ...
Cached Medicine Technology:Custom Spine Announces the Expansion of its Sales Management Team 2VetCentric and ImproMed, Inc.(R) Announce One-Click Home Delivery Integration 2VetCentric and ImproMed, Inc.(R) Announce One-Click Home Delivery Integration 3
(Date:8/3/2015)... ... August 04, 2015 , ... Approved provider ... line up of live courses for the month of August. , Physical therapy ... individually or by purchasing a Physical Therapy Flex package. Flex packages allow therapists ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sutter Health’s California Pacific Medical ... (COO) at CPMC. Hamila will start in her role effective immediately and will have ... has worked at CPMC and Sutter Health for about 15 years, including the past ...
(Date:8/3/2015)... ... August 03, 2015 , ... The Workgroup for Electronic Data ... IT to create efficiencies in healthcare information exchange, announced the release of its findings ... and Human Services (HHS) Secretary, WEDI shared survey results and recommendations ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... ruled in favor of the firm’s client Rebecca Hamsher, deciding that in accordance ... must reimburse benefits for Hamsher’s residential treatment for bulimia, depression and other mental ...
(Date:8/3/2015)... ... August 03, 2015 , ... A recent ... an overwhelming number of Hispanics believe people can positively affect their diabetes, few ... participants queried said making diet changes was important. Far fewer participants mentioned the ...
Breaking Medicine News(10 mins):Health News:Elite Online CE Provider Announces Schedule of Live Courses For Florida Physical Therapy Continuing Education 2Health News:Elite Online CE Provider Announces Schedule of Live Courses For Florida Physical Therapy Continuing Education 3Health News:Hamila Kownacki, RN Appointed as New Chief Operating Officer at CPMC 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4
... The National Patient Safety Foundation,(NPSF) today announced that ... leading health care solutions providers to work,alongside the ... their families -- all with the single convergent ... http://www.newscom.com/cgi-bin/prnh/20080307/AQF053LOGO ), "We are excited to be ...
... of Pennsylvania School of Medicine can now explain how ... in the blood stream at any one time. These ... fight infections. , "There is a steady state number ... says senior author Michael P. Cancro, PhD, Professor of ...
... with inflammatory diseases such as rheumatoid arthritis now have ... biologic disease-modifying antirheumatic drugs (DMARDs). These drugs, derived by ... of the disease rather than simply treating the symptoms. ... because a one month,s supply may cost 100 times ...
... Henri de Toulouse-Lautrec suffered, is a genetic disease characterized ... window into how joints are destroyed by arthritis. It ... cathepsin K which hampers osteoclasts (the cells that break ... poor bone resorption and dense, brittle bones. , ...
... Co-Pays, HOUSTON, Nov. 4 US Oncology today ... pharmacy, has,exceeded the $10 million mark in assisting more ... Care Advantage in August 2006., "It was important ... patient access to oral chemotherapies by easing the financial,burdens ...
... MYL ),today announced that its subsidiary Mylan ... and Drug Administration (FDA) for its,Abbreviated New Drug ... and 750 mg. Levetiracetam Tablets are the generic ... Mylan,s Vice Chairman and CEO, commented: "We are,extremely ...
Cached Medicine News:Health News:AmerisourceBergen Joins National Patient Safety Foundation Corporate Council 2Health News:Penn scientists show how body determines optimal amount of germ-fighting B cells 2Health News:Medicaid policies vary widely for rheumatoid arthritis drugs 2Health News:Genetic disorder sheds light on enzyme's role in bone metabolism 2Health News:OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $10 Million Milestone in Patient Financial Assistance 2Health News:OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $10 Million Milestone in Patient Financial Assistance 3Health News:Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: